Drugs / SYNB1618
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04984525 | Jul → Dec 2021 | — | Synlogic | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03516487 | Apr 2018 → Jun 2019 | phenylketonuria | Synlogic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04534842 | Aug 2020 → Oct 2022 | phenylketonuria | Synlogic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYNB1618 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03516487 ↗ |
| Modality | Other / unclassified | “The development of therapeutics depends on predictions of clinical activity from pre-clinical data. We have previously described SYNB1618, an engineered bacterial therapeutic...” PMID 34294862 ↗ Jul 2021 |
| Route | Oral | “HV subjects receive a single oral dose of SYNB1618” NCT03516487 ↗ |